Rapirosiran (ALN-HSD) Investigational HSD17B13-silencing RNAi therapy licensed to Regeneron, in Phase 2 development for metabolic dysfunction-associated steatohepatitis and its underlying liver disease.
Visit productCosigns Received
Be the first Cosign
Put your name behind Rapirosiran (ALN-HSD).
Add it to your Products I use list and share why you use it.